Lipella Pharmaceuticals Inc. (LIPO)
OTCMKTS · Delayed Price · Currency is USD
0.1400
-0.0300 (-17.65%)
May 20, 2026, 3:20 PM EST
Lipella Pharmaceuticals Revenue
Lipella Pharmaceuticals had revenue of $389.78K in the twelve months ending September 30, 2025, down -19.39% year-over-year. In the year 2024, Lipella Pharmaceuticals had annual revenue of $536.36K with 19.29% growth.
Revenue (ttm)
389.78K
Revenue Growth
-19.39%
P/S Ratio
1.66
Revenue / Employee
64.96K
Employees
7
Market Cap
646.46K
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 536.36K | 86.74K | 19.29% |
| Dec 31, 2023 | 449.62K | 265.46K | 144.15% |
| Dec 31, 2022 | 184.16K | -75.19K | -28.99% |
| Dec 31, 2021 | 259.35K | -702.34K | -73.03% |
| Dec 31, 2020 | 961.68K | 266.94K | 38.42% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Evofem Biosciences | 20.24M |
| SQZ Biotechnologies Company | 12.12M |
| Emmaus Life Sciences | 12.03M |
| Avenue Therapeutics | 1.40M |
| CNBX Pharmaceuticals | 40.64K |
| Halberd | 6.94K |
| Aibotics | 2.18K |
Lipella Pharmaceuticals News
- 7 weeks ago - Lipella Pharmaceuticals Inc. Files Voluntary Petitions for Relief Under Chapter 11 - GlobeNewsWire
- 6 months ago - Lipella Pharmaceuticals Quarterly report: Q3 2025 - Filings
- 8 months ago - Lipella Pharmaceuticals Transcript: Life Sciences Virtual Investor Forum 2025 - Transcripts
- 8 months ago - Lipella Pharmaceuticals announces final results from Phase 2a study of LP-10 - TheFly
- 8 months ago - Lipella Pharmaceuticals to Present at Zacks SCR Life Sciences Virtual Investor Forum and Report Final Phase 2a Results in Oral Lichen Planus - PRNewsWire
- 10 months ago - Lipella Pharmaceuticals Quarterly report: Q2 2025 - Filings
- 11 months ago - Lipella Pharmaceuticals Issues Letter from the CEO to Stockholders Following Nasdaq Delisting - GlobeNewsWire
- 11 months ago - Lipella Pharmaceuticals Announces Delisting from Nasdaq Capital Market - GlobeNewsWire